Brokerages Set Polarityte Inc (PTE) Target Price at $34.33
Shares of Polarityte Inc (NASDAQ:PTE) have received an average rating of “Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $34.33.
Several brokerages have recently weighed in on PTE. Zacks Investment Research upgraded shares of Polarityte from a “sell” rating to a “hold” rating in a research note on Tuesday, March 26th. ValuEngine cut shares of Polarityte from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. Cantor Fitzgerald set a $65.00 price objective on shares of Polarityte and gave the stock a “buy” rating in a research note on Tuesday, March 19th. Evercore ISI began coverage on shares of Polarityte in a research note on Wednesday, March 20th. They issued an “outperform” rating and a $26.00 price objective on the stock. Finally, Oppenheimer began coverage on shares of Polarityte in a research note on Tuesday, January 29th. They issued an “outperform” rating and a $30.00 price objective on the stock.
An institutional investor recently bought a new position in Polarityte stock. Comprehensive Portfolio Management LLC bought a new position in shares of Polarityte Inc (NASDAQ:PTE) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 21,702 shares of the company’s stock, valued at approximately $232,000. Comprehensive Portfolio Management LLC owned 0.10% of Polarityte at the end of the most recent quarter. 54.85% of the stock is owned by institutional investors.
Polarityte Company Profile
PolarityTE, Inc, a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services.
Receive News & Ratings for Polarityte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polarityte and related companies with MarketBeat.com's FREE daily email newsletter.